What does the FDA say about stopping HRT

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

According to FDA.gov, hormone therapy should be used at the lowest effective dose for the shortest duration needed, and women should periodically reassess with a qualified prescriber whether they still need it. The FDA does not require a specific method for stopping hormone therapy, and does not state that gradual tapering is safer than stopping all at once. You may stop either gradually or all at once based on guidance from your prescriber.

Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

What the FDA's guidance really means

According to FDA.gov, the FDA focuses on two principles: using hormone therapy only as long as it is providing benefit, and checking in regularly with your clinician. It does not instruct women to taper, nor does it warn against stopping suddenly. Both methods are considered medically acceptable. The main practical difference is comfort: some women experience fewer returning symptoms when they taper gradually, though this is a matter for discussion with a qualified prescriber.

How stopping HRT works in real life

• Both methods are medically acceptable: According to FDA.gov, the FDA leaves the choice to the woman and her qualified prescriber. Some stop overnight; others reduce dose over weeks or months.
• No evidence of harm from stopping suddenly: Stopping abruptly does not cause dangerous withdrawal. The primary concern is that symptoms like hot flashes may return.
• Tapering may ease comfort: Stretching out dose reductions may soften the return of symptoms, especially for those who are sensitive to hormonal shifts.
• Returning symptoms are not dangerous: They may be bothersome, but they reflect your body returning to its non-HRT hormone level.
• Restarting may be considered if needed: According to FDA.gov, adjusting or restarting your regimen is an option if symptoms become disruptive — this decision should be made with a qualified prescriber.

What the FDA wants women to keep in mind

• Review treatment yearly: According to FDA.gov, women should reassess whether hormone therapy is still improving quality of life at each annual visit.
• Stay on the lowest effective dose: This approach aims to reduce long-term risks while still providing symptom relief, per FDA.gov guidance.
• Discuss your personal risks with a qualified prescriber: Conditions like breast cancer history, blood clots, or uncontrolled hypertension affect the risk–benefit balance and require individual evaluation.